ARTICLE | Company News
BridgeBio launches rare genetic disorder subsidiary
June 13, 2018 11:23 PM UTC
BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary this week, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders.
CoA CEO Shafique Virani told BioCentury that the compounds directly target pantothenate kinase 1 (PANK1) and PANK3 to up-regulate coenzyme A. The candidates were in-licensed from St. Jude Children's Research Hospital (Memphis, Tenn.). ...
BCIQ Company Profiles
BCIQ Target Profiles